Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1996-12-04
2001-03-13
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S204100, C424S489000, C435S459000
Reexamination Certificate
active
06200959
ABSTRACT:
CROSS-REFERENCE TO RELATED APPLICATIONS
Not applicable.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
Not applicable.
BACKGROUND OF THE INVENTION
The present invention relates to the general field of genetic vaccines and relates, in particular, to genetic agents delivered into the skin or mucosal tissues of animals to induce an immune response, and more particularly to genetic vaccines for viral pathogens delivered into skin or mucosal tissues by particle acceleration.
In particular, the present invention relates to the field of genetic vaccines that protect human and non-human vertebrates against infection by viruses of the Filovirus genus (Family Filoviridae). The known filoviruses include the Ebola virus Reston, Ebola virus Sudan, Ebola virus Zaire and Marburg virus (strain Musoke and strain Ravn). Filoviruses are non-segmented, negative stranded enveloped ssRNA viruses having a vertebrate host range. The range of possible invertebrate hosts (such as, but not limited to, arthropods) is not known. A glycoprotein inserted in the viral envelope may mediate virus entry into host cells.
The Marburg virus glycoprotein (170 kD) is a type I transmembrane protein. The carbohydrate structures account for more than 50% of the molecular weight of the protein. The Ebola virus glycoproteins (125 kD) appear to have similar carbohydrate structures to the Marburg glycoproteins, except insofar as the Ebola glycoproteins are terminally sialated.
Marburg and Ebola viruses cause severe hemorrhagic fever in humans and in laboratory primates. Ebola-Zaire strain appears to be more deadly than either the Sudan strain or the Marburg virus. After an incubation period of four to sixteen days, sudden fever, chills, headache, anorexia and myalgia appear. Nausea, vomiting, sore throat, abdominal pain and diarrhea soon follow. Most patients develop severe hemorrhaging between about days five and seven. Death usually occurs between seven and sixteen days.
In patients, antibodies directed primarily against the surface glycoproteins of Marburg and Ebola viruses can be detected as early as ten to fourteen days after infection. However, it is not entirely clear that such antibodies can prevent the overt manifestations of the disease.
The vaccination of individuals to render the vaccinated individuals resistant to the development of infectious disease is one of the oldest forms of preventive care in medicine. Previously, vaccines for viral and bacterial pathogens for pediatric, adult, and veterinary usage were derived directly from the infectious organisms and could be categorized as falling into one of three broad categories: live attenuated, killed, and subunit vaccines. Although the three categories of vaccines differ significantly in their development and mode of actions, the administration of any of these three categories of these vaccines is intended to result in production of specific immunological responses to the pathogen, following one or more inoculations of the vaccine. The resulting immunological responses may or may not completely protect the individual against subsequent infection, but will usually prevent the manifestation of disease symptoms and significantly limit the extent of any subsequent infection.
The techniques of modern molecular biology have enabled a variety of new vaccine strategies to be developed which are in various stages of pre-clinical and clinical development. The intent of these efforts is not only to produce new vaccines for old diseases, but also to yield new vaccines for infectious diseases in which classical vaccine development strategies have so far proven unsuccessful. Notably, the recent identification and spread of immunodeficiency viruses is an example of a pathogen for which classical vaccine development strategies have not yielded effective control to date.
The first broad category of classical vaccine is live attenuated vaccines. A live attenuated vaccine represents a specific strain of the pathogenic virus, or bacterium, which has been altered so as to lose its pathogenicity, but not its ability to infect and replicate in humans. Live attenuated vaccines are regarded as the most effective form of vaccine because they establish a true infection within the individual. The replicating pathogen and its infection of human cells stimulates both humoral and cellular compartments of the immune system as well as long-lasting immunological memory. Thus, live attenuated vaccines for viral and intracellular bacterial infections stimulate the production of neutralizing antibodies, as well as cytotoxic T-lymphocytes (CTLs), usually after only a single inoculation.
The ability of live attenuated vaccines to stimulate the production of CTLs is believed to be an important reason for the comparative effectiveness of live attenuated vaccines. CTLs are recognized as the main component of the immune system responsible for the actual clearing of viral and intracellular bacterial infections. CTLs are triggered by the production of foreign proteins in individual infected cells of the hosts, the infected cells processing the antigen and presenting the specific antigenic determinants on the cell surface for immunological recognition.
The induction of CTL immunity by attenuated vaccines is due to the establishment of an actual, though limited, infection in the host cells including the production of foreign antigens in the individual infected cells. The vaccination process resulting from a live attenuated vaccine also results in the induction of immunological memory, which manifests itself in the prompt expansion of specific CTL clones and antibody-producing plasma cells in the event of future exposure to a pathogenic form of the infectious agent, resulting in the rapid clearing of this infection and practical protection from disease.
An important disadvantage of live attenuated vaccines is that they have an inherent tendency to revert to a new virulent phenotype through random genetic mutation. Although statistically such a reversion is a rare event for attenuated viral vaccines in common use today, such vaccines are administered on such a large scale that occasional reversions are inevitable, and documented cases of vaccine-induced illnesses exist. In addition, complications are sometimes observed when attenuated vaccines lead to the establishment of disseminated infections due to a lowered state of immune system competence in the vaccine recipient. Further limitations on the development of attenuated vaccines are that appropriate attenuated strains can be difficult to identify for some pathogens and that the frequency of mutagenic drift for some pathogens can be so great that the risk associated with reversion are simply unacceptable. A virus for which this latter point is particularly well exemplified is the human immunodeficiency virus (HIV) in which the lack of an appropriate animal model, as well as an incomplete understanding of its pathogenic mechanism, makes the identification and testing of attenuated mutant virus strains effectively impossible. Even if such mutants could be identified, the rapid rate of genetic drift and the tendency of retroviruses, such as HIV, to recombine would likely lead to an unacceptable level of instability in any attenuated phenotype of the virus. Due to these complications, the production of a live attenuated vaccine for certain viruses may be unacceptable, even though this approach efficiently produces the desired cytotoxic cellular immunity and immunological memory.
The second category of vaccines consists of killed and subunit vaccines. These vaccines consist of inactivated whole bacteria or viruses, or their purified components. These vaccines are derived from pathogenic viruses or bacteria which have been inactivated by physical or chemical processing, and either the whole microbial pathogen, or a purified component of the pathogen, is formulated as the vaccine. Vaccines of this category can be made relatively safe, through the inactivation procedure, but there is a trade-off between the extent of inactivation and the extent o
Fuller Deborah L.
Haynes Joel R.
Jahrling Peter B.
Schmaljohn Alan
Schmaljohn Connie S.
McCracken Thomas P.
Mosher Mary E.
PowerJect Vaccines Inc.
LandOfFree
Genetic induction of anti-viral immune response and genetic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genetic induction of anti-viral immune response and genetic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetic induction of anti-viral immune response and genetic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2470653